Method to diminish cd83 expression in monocyte-derived dendritic cells, t-cells and b-cells by RNAi

Simple SummaryContent extracted from patent full text and abstract with AI.

This patent describes a method to specifically reduce the expression of CD83, a key surface molecule on dendritic cells (DCs), T-cells, and B-cells, using RNA interference (RNAi) techniques such as small interfering RNA (siRNA) or short hairpin RNA (shRNA). By targeting CD83 with RNAi, the immune system’s activation—particularly the stimulation of T-cell proliferation by dendritic cells—can be selectively modulated. This method enables the suppression of undesired immune responses, with potential uses in cell therapy (such as preparing modified immune cells or grafts) and direct therapeutic interventions for immune-related conditions.

Use CasesContent extracted from patent full text and abstract with AI.

• Prevention and treatment of autoimmune diseases by reducing excessive immune activation.
• Treatment of allergic reactions by suppressing overactive immune responses mediated by DCs, T-cells, or B-cells.
• Prevention of graft rejection in organ transplantation by lowering the immune system’s recognition and rejection of foreign tissue.
• Preparation of autologous (patient-derived) dendritic, T-, or B-cells for ex vivo modification and subsequent re-infusion to induce immune tolerance.
• Treatment of chronic inflammatory and immune-mediated conditions such as multiple sclerosis, Crohn’s disease, rheumatoid arthritis, and psoriasis.
• Potential adjunct therapy for immunosuppressive regimens in transplantation or severe inflammatory syndromes.

BenefitsContent extracted from patent full text and abstract with AI.

• Highly specific suppression of CD83, minimizing off-target effects and avoiding broad immune suppression.
• Long-lasting and efficient reduction of CD83 expression, ensuring a durable therapeutic effect.
• No need for chemical inhibitors or viral vectors, reducing the risk of unwanted side effects and toxicity.
• Preservation of other dendritic cell surface molecules (e.g., CD80, CD86), ensuring that the cells retain most of their functional characteristics except for CD83-mediated interactions.
• Ability to perform the method ex vivo for safer and personalized cell therapy interventions.
• Versatility to modify not only dendritic cells but also T-cells and B-cells, broadening the range of immunotherapy applications.
• Potential to decrease both the immunogenicity and rejection risk of transplanted tissues and organs.

Technical Classifications (CPCs)

Inventors & Applicants

Patent Abstract

The present invention provides a RNAi method for the specific reduction of CD83 surface expression by dendritic cells (DCs), T-cells and B-cells, especially by DCs. This method can be used to inhibit the T cell activating ability of DCs and for reduction or suppression of T-cell proliferation in immune response. The invention further provides a RNAi agent targeted to the CD83 transcript and dendritic cells obtainable by the method. A method and a medicament for the treatment of a clinical condition which is based on the negative effect of a CD83 mediated interaction between mature DCs and T-cells in a mammalian subject, and a method for decreasing the immunogenicity and rejection potential of a graft using said RNAi agent are also provided.